English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Live attenuated influenza virus production in batch high cell density cultivation of suspension AGE1.CR.pIX cells

Lohr, V., Genzel, Y., Katinger, D., Jordan, I., Sandig, V., & Reichl, U. (2012). Live attenuated influenza virus production in batch high cell density cultivation of suspension AGE1.CR.pIX cells. Poster presented at Vaccine Technology IV, Albufeira, Portugal.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-88E3-7 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0025-1AA1-D
Genre: Poster

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Lohr, Verena1, Author              
Genzel, Yvonne1, Author              
Katinger, D., Author
Jordan, I., Author
Sandig, V., Author
Reichl, Udo1, 2, Author              
Affiliations:
1Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society, ou_1738140              
2Otto-von-Guericke-Universität Magdeburg, ou_1738156              

Content

show
hide
Free keywords: -
 Abstract: Most influenza vaccines are trivalent inactivated split or subunit vaccines administered intramuscular. Alternatively, live attenuated influenza vaccine (LAIV) induce a more efficient immunological response and can be applied intranasal [1]. The attenuated viruses are generated by reassorting 6 backbone genes of cold-adapted (ca) viruses replicating best at 25 °C with the respective genes for HA and NA of the seasonal strains. Vaccine is then produced at 33°C in eggs or cell culture. However, in a screen for possible production cell lines most cell lines exhibited only low permissivities or do not replicate all strains. Only with MDCK and Vero cells high titers of approximately 108 pfu/mL could be achieved [2]. Here, we report on an evaluation of the avian designer cell line AGE1.CR.pIX for LAIV production. Before infection experiments were done, adaptations of Vero-adapted LAIV A and B strains were carried out throughout three passages to improve replication. In scouting experiments, promising titers of ≥108 viruses/mL were achieved in small-scale cultures. In a next step, lab-scale bioreactor production aiming at high cell densities of >4x106 cells/mL in batch mode was evaluated. Up to 5x106 cells/mL could be infected in these studies without loss of cell-specific productivity. Overall, yields achieved with this suspension cell line were comparable to titers obtained with Vero or MDCK cells [3]. Both process steps (cell proliferation and virus production) took place in a chemically defined medium, favoring this approach over processes described for MDCK or Vero cells. In summary, the evaluated cell line AGE1.CR.pIX was shown to be suitable for production of LAIV strains to significant titers and thus provide a fully chemically-defined suspension process.

Details

show
hide
Language(s): eng - English
 Dates: 2012
 Publication Status: Not specified
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: eDoc: 610734
 Degree: -

Event

show
hide
Title: Vaccine Technology IV
Place of Event: Albufeira, Portugal
Start-/End Date: 2012-05-20 - 2012-05-25

Legal Case

show

Project information

show

Source

show